Malignancy-associated metabolic profiling of human glioma cell lines using 1H NMR spectroscopy

Abstract

BackgroundAmbiguity in malignant transformation of glioma has made prognostic diagnosis very challenging. Tumor malignant transformation is closely correlated with specific alterations of the metabolic profile. Exploration of the underlying metabolic alterations in glioma cells of different malignant degree is therefore vital to develop metabolic biomarkers for prognosis monitoring.MethodsWe conducted 1H nuclear magnetic resonance (NMR)-based metabolic analysis on cell lines (CHG5, SHG44, U87, U118, U251) developed from gliomas of different malignant grades (WHO II and WHO IV). Several methods were applied to analyze the 1H-NMR spectral data of polar extracts of cell lines and to identify characteristic metabolites, including principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), fuzzy c-means clustering (FCM) analysis and orthogonal projection to latent structure with discriminant analysis (OPLS-DA). The expression analyses of glial fibrillary acidic protein (GFAP) and matrix metal proteinases (MMP-9) were used to assess malignant behaviors of cell lines. GeneGo pathway analysis was used to associate characteristic metabolites with malignant behavior protein markers GFAP and MMP-9.ResultsStable and distinct metabolic profiles of the five cell lines were obtained. The metabolic profiles of the low malignancy grade group (CHG5, SHG44) were clearly distinguished from those of the high malignancy grade group (U87, U118, U251). Seventeen characteristic metabolites were identified that could distinguish the metabolic profiles of the two groups, nine of which were mapped to processes related to GFAP and MMP-9. Furthermore, the results from both quantitative comparison and metabolic correlation analysis indicated that the significantly altered metabolites were primarily involved in perturbation of metabolic pathways of tricarboxylic acid (TCA) cycle anaplerotic flux, amino acid metabolism, anti-oxidant mechanism and choline metabolism, which could be correlated with the changes in the glioma cells’ malignant behaviors.ConclusionsOur results reveal the metabolic heterogeneity of glioma cell lines with different degrees of malignancy. The obtained metabolic profiles and characteristic metabolites are closely associated with the malignant features of glioma cells, which may lay the basis for both determining the molecular mechanisms underlying glioma malignant transformation and exploiting non-invasive biomarkers for prognosis monitoring.Electronic supplementary materialThe online version of this article (doi:10.1186/1476-4598-13-197) contains supplementary material, which is available to authorized users.

Analysis of metabolome changes in the HepG2 cells of apatinib treatment by using the NMR‐based metabolomics

“…The NMR spectra were gathered in the NMR spectrometer (Bruker AVANCE III 600 Hz HD; Bruker BioSpin, Germany) with TXI probe at 298 K. The NOESYPR1D pulse ([RD‐90°‐t 1 ‐90°‐τ m ‐90°‐acq]) was applied to the process of acquirement. The detailed parameters of acquired process were referred to the previous works …”

Metabolomic signature of brain cancer

“…Recently, metabolomics studies indicated that “metabolic phenotypes” possess great potential for development of novel therapeutics and monitoring of treatment response in brain tumors . Therefore, a relevant number of studies focus on the metabolic characterization of immortalized and primary isolates or cultured cells which include neurones, glial cells, astrocytes, and neural stem cells and their benign and malignant counterparts . Updated lists of the metabolic alterations in adult and paediatric brain tumors associated with neuroblastoma, GBM (low and high grade gliomas), meningioma, and other rare malignant brain tumors are reported in Tables and .…”

The effect of neurosphere culture conditions on the cellular metabolism of glioma cells

“…Detection and targeting of miss-regulated choline-, myo-inositol-, creatine-, and glycine-metabolism has been de scribed to have potential utility in the diagnosis and treatment of malignant gliomas [2][3][4]13,16,19]. This is, to our knowledge, the hitherto first link of changes in those oncometabolites [4,25] to variations in cell culture conditions of glioma cells. Interspectral co-analysis of metabolite concentrations under the two propagation conditions identified reductions in ratios of phosphocholine to glycerophosphocholine (PC/GPC) and glycine to total choline (Gly/tCho) but increases in the quotient of total choline to total creatine (tCho/tCre) and PC/tCre, as well as Gly/myo-inositol (Gly/myo).…”